Advertisement
Canada markets open in 7 hours 37 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7305
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    88,012.16
    -3,377.45 (-3.70%)
     

  • CMC Crypto 200

    1,389.06
    -35.04 (-2.46%)
     

  • GOLD FUTURES

    2,329.50
    -8.90 (-0.38%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    -4.5980 (-49.71%)
     

  • NASDAQ futures

    17,435.50
    -229.00 (-1.30%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,633.48
    -826.60 (-2.15%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

FSD Pharma Acquires Prismic Pharmaceuticals

ME Staff

FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) and US-based specialty R&D pharmaceutical company Prismic Pharmaceuticals finalized a deal for the acquisition of all of the issued and outstanding securities of Prismic by FSD Pharma.

Under to the terms of a securities exchange agreement, FSD Pharma has acquired all outstanding common and preferred shares of Prismic for approximately US$17.5 million, satisfied by the issuance of approximately 102.7 million Class B subordinate voting shares of FSD Pharma at a deemed price of C$0.2275 per FSD share.

In addition, FSD Pharma has agreed to assume approximately US$3.05 million of outstanding Prismic long- and short-term liabilities. All of the outstanding Prismic stock options and warrants have been converted into options and warrants to purchase FSD shares.

FSD Pharma Executive Co-Chairman and CEO Raza Bokhari states that “the Prismic acquisition represents strategic depth in the vision and mission of FSD Pharma and signals a paradigm shift in the overall outlook of the company.”

The post FSD Pharma Acquires Prismic Pharmaceuticals appeared first on Market Exclusive.